title: Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis.
abstract: BACKGROUND
  Psoriasis is a chronic relapsing skin disorder that affects about 2% of the U.S. population and involves the scalp approximately 50% of the time. Topical corticosteroids, including betamethasone valerate, have been used effectively in the treatment of corticosteroid-responsive dermatoses of the skin and scalp. Betamethasone valerate (BMV) in foam vehicle (Luxiq) is designed to improve patient compliance with topical therapy. Superior efficacy over a BMV lotion preparation has been demonstrated with twice-daily use. Even greater compliance would be expected if the drug is effective with once-daily application.
  
  
  OBJECTIVE
  To compare the efficacy of the betamethasone valerate foam (Luxiq) in the treatment of scalp psoriasis following once-daily versus twice-daily dosing.
  
  
  METHODS
  Seventy-nine patients with moderate to severe scalp psoriasis from seven centers were enrolled and treated with BMV foam either once a day or twice a day for four weeks. The physician-grader was blinded to the treatment regimen, and the subjects were randomly assigned to either once-daily or twice-daily dosing in a 1:1 ratio.
  
  
  RESULTS
  The signs of psoriasis (plaque thickness, scaling, and erythema) were assessed before and after treatment. The investigator's and the patients' global assessments were also evaluated. The composite score improved from 7.7 +/- 2.1 to 3.0 +/- 2.2 with twice-a-day use and from 8.1 +/- 2.2 to 3.9 +/- 2.8 with once-daily use (p > 0.05 for the difference between groups).
  
  
  CONCLUSIONS
  BMV foam is effective for scalp psoriasis with both once-a-day and twice-a-day use. This feature of the BMV foam is encouraging for expected improvement in clinical use.
authors.affiliation: Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA. sfeldman@wfubmc.edu
authors.forename: S R
authors.initials: SR
authors.lastname: Feldman
authors.forename: S M
authors.initials: SM
authors.lastname: Ravis
authors.forename: A B
authors.initials: AB
authors.lastname: Fleischer
authors.forename: A
authors.initials: A
authors.lastname: McMichael
authors.forename: E
authors.initials: E
authors.lastname: Jones
authors.forename: R
authors.initials: R
authors.lastname: Kaplan
authors.forename: J
authors.initials: J
authors.lastname: Shavin
authors.forename: J
authors.initials: J
authors.lastname: Weiss
authors.forename: J K
authors.initials: JK
authors.lastname: Bartruff
authors.forename: D L
authors.initials: DL
authors.lastname: Levin
authors.forename: J
authors.initials: J
authors.lastname: Del Rosso
authors.forename: N
authors.initials: N
authors.lastname: Kpea
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001623:Betamethasone / Q000008:administration & dosage*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012536:Scalp Dermatoses / Q000188:drug therapy*; D016037:Single-Blind Method
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D001623:Betamethasone